Bortezomib

Generic Name
Bortezomib
Brand Names
Velcade, Bortezomib Accord, Bortezomib Hospira, Bortezomib Fresenius Kabi, Bortezomib Sun
Drug Type
Small Molecule
Chemical Formula
C19H25BN4O4
CAS Number
179324-69-7
Unique Ingredient Identifier
69G8BD63PP
Background

Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib.

Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.

Indication

Bortezomib is indicated for the treatment of adults with multiple myeloma or mantle cell lymphoma.

Associated Conditions
Mantle Cell Lymphoma (MCL), Multiple Myeloma (MM)
Associated Therapies
-
Clinical Trials
Related News

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

First Posted Date
2019-09-16
Last Posted Date
2024-05-17
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
144
Registration Number
NCT04091126
Locations
🇬🇧

GSK Investigational Site, London, United Kingdom

A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

First Posted Date
2019-08-20
Last Posted Date
2019-08-20
Lead Sponsor
Zhejiang Cancer Hospital
Target Recruit Count
54
Registration Number
NCT04061772
Locations
🇨🇳

Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

First Posted Date
2019-08-12
Last Posted Date
2024-03-28
Lead Sponsor
Larysa Sanchez
Target Recruit Count
18
Registration Number
NCT04052880
Locations
🇺🇸

Icahn School of Medicine at Mount Sinai, New York, New York, United States

Trial to Evaluate Efficacy and Safety of Bortezomib in Patients with Severe Autoimmune Encephalitis

Phase 2
Recruiting
Conditions
Autoimmune Encephalitis
Interventions
Drug: Placebo
Drug: Bortezomib
First Posted Date
2019-06-20
Last Posted Date
2024-12-11
Lead Sponsor
Jena University Hospital
Target Recruit Count
50
Registration Number
NCT03993262
Locations
🇩🇪

Ludwig-Maximilians-Universität München, Klinikum Großhadern, München, Bayern, Germany

🇩🇪

Universitätsklinikum Würzburg, Würzburg, Bayern, Germany

🇩🇪

Medizinische Hochschule Hannover, Hannover, Niedersachen, Germany

and more 14 locations

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

First Posted Date
2019-06-18
Last Posted Date
2024-11-28
Lead Sponsor
Celgene
Target Recruit Count
424
Registration Number
NCT03989414
Locations
🇺🇸

Local Institution - 110, Winston-Salem, North Carolina, United States

🇨🇿

Local Institution - 802, Brno, Czechia

🇨🇿

Local Institution - 801, Ostrava-Poruba, Czechia

and more 46 locations

BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

First Posted Date
2019-06-12
Last Posted Date
2019-06-12
Lead Sponsor
Peking Union Medical College Hospital
Target Recruit Count
30
Registration Number
NCT03982771
Locations
🇨🇳

Peking Union Medical College Hospital, Beijing, Beijing, China

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

First Posted Date
2019-06-12
Last Posted Date
2024-04-30
Lead Sponsor
Takeda
Target Recruit Count
50
Registration Number
NCT03984097
Locations
🇺🇸

American Oncology Partners of Maryland, PA, Bethesda, Maryland, United States

🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

🇺🇸

Pacific Cancer Care, Monterey, California, United States

and more 6 locations

High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Phase 2
Completed
Conditions
GVHD
Interventions
Drug: Bortezomib
Drug: Cyclophosphamide
First Posted Date
2019-05-10
Last Posted Date
2024-03-07
Lead Sponsor
NYU Langone Health
Target Recruit Count
23
Registration Number
NCT03945591
Locations
🇺🇸

New York University School of Medicine, New York, New York, United States

Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

First Posted Date
2019-05-08
Last Posted Date
2024-06-21
Lead Sponsor
Emory University
Target Recruit Count
49
Registration Number
NCT03942224
Locations
🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1
Terminated
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma
Interventions
Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat
First Posted Date
2019-03-18
Last Posted Date
2024-03-04
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
2
Registration Number
NCT03878524
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy